Merlina Sulistio1,2, Robert Wojnar3, Seraphina Key4, Justin Kwok4, Ziad Al-Rubaie5, Natasha Michael3,4,5. 1. Palliative and Supportive Care Research Department, Cabrini Health, 646 High St, Prahran, Melbourne, VIC, 3181, Australia. msulistio@cabrini.com.au. 2. Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia. msulistio@cabrini.com.au. 3. Palliative and Supportive Care Research Department, Cabrini Health, 646 High St, Prahran, Melbourne, VIC, 3181, Australia. 4. Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia. 5. School of Medicine, University of Notre Dame Australia Sydney, Sydney, NSW, Australia.
Abstract
PURPOSE: Cancer-induced bone pain (CIBP) can be challenging to manage in advanced cancer. The unique properties of methadone may have a role in refractory CIBP. We aimed to evaluate the analgesic effects of methadone for CIBP when other opioids are ineffective or intolerable. METHODS: A retrospective study of palliative care inpatients rotated to methadone from another opioid for CIBP over a 4-year period. Primary outcome was ≥ 30% reduction in pain intensity (11-point numeric rating scale) from baseline to completion of methadone rotation (MR). Secondary outcomes were ≥ 50% reduction in pain intensity and changes in long-acting and breakthrough opioid requirements. RESULTS: Ninety-four eligible patients completed MR for the following reasons: poor pain control (72.3%), opioid toxicities (4.3%) or both (23.4%). On completion of MR, 70.2% and 53.2% achieved a ≥ 30% and ≥ 50% reduction in pain respectively, with mean pain intensity score reduced from 5.6 (SD = 2.1) at baseline to 2.6 (SD = 2.5) (p < 0.001). Mean calculated daily methadone dose pre-MR was 25.7 mg (SD = 10.9), with 72.3% of patients requiring a lower dose on completion of MR (mean 17.0 mg, SD = 8.5). The mean number of breakthrough opioid analgesia used a day reduced from 3.4 (SD = 2.3) to 1.8 (SD = 1.7) (p < 0.001). CONCLUSIONS: MR for CIBP may result in reduction in pain intensity, when other opioids are ineffective or intolerable, with patients requiring reduced overall dosing of their long-acting opioid and frequency of breakthrough opioid use.
PURPOSE:Cancer-induced bone pain (CIBP) can be challenging to manage in advanced cancer. The unique properties of methadone may have a role in refractory CIBP. We aimed to evaluate the analgesic effects of methadone for CIBP when other opioids are ineffective or intolerable. METHODS: A retrospective study of palliative care inpatients rotated to methadone from another opioid for CIBP over a 4-year period. Primary outcome was ≥ 30% reduction in pain intensity (11-point numeric rating scale) from baseline to completion of methadone rotation (MR). Secondary outcomes were ≥ 50% reduction in pain intensity and changes in long-acting and breakthrough opioid requirements. RESULTS: Ninety-four eligible patients completed MR for the following reasons: poor pain control (72.3%), opioid toxicities (4.3%) or both (23.4%). On completion of MR, 70.2% and 53.2% achieved a ≥ 30% and ≥ 50% reduction in pain respectively, with mean pain intensity score reduced from 5.6 (SD = 2.1) at baseline to 2.6 (SD = 2.5) (p < 0.001). Mean calculated daily methadone dose pre-MR was 25.7 mg (SD = 10.9), with 72.3% of patients requiring a lower dose on completion of MR (mean 17.0 mg, SD = 8.5). The mean number of breakthrough opioid analgesia used a day reduced from 3.4 (SD = 2.3) to 1.8 (SD = 1.7) (p < 0.001). CONCLUSIONS: MR for CIBP may result in reduction in pain intensity, when other opioids are ineffective or intolerable, with patients requiring reduced overall dosing of their long-acting opioid and frequency of breakthrough opioid use.
Entities:
Keywords:
Bone pain; Cancer pain; Methadone; Opioid; Opioid rotation; Palliative care
Authors: Christopher M Peters; Joseph R Ghilardi; Cathy P Keyser; Kazufumi Kubota; Theodore H Lindsay; Nancy M Luger; David B Mach; Matthew J Schwei; Molly A Sevcik; Patrick W Mantyh Journal: Exp Neurol Date: 2005-05 Impact factor: 5.330
Authors: Shunsuke Tsuzuki; Sun Hee Park; Matthew R Eber; Christopher M Peters; Yusuke Shiozawa Journal: Int J Urol Date: 2016-08-03 Impact factor: 3.369
Authors: Maria Teresa Greco; Anna Roberto; Oscar Corli; Silvia Deandrea; Elena Bandieri; Silvio Cavuto; Giovanni Apolone Journal: J Clin Oncol Date: 2014-11-17 Impact factor: 44.544
Authors: Marie Fallon; Peter J Hoskin; Lesley A Colvin; Susan M Fleetwood-Walker; Douglas Adamson; Anthony Byrne; Gordon D Murray; Barry J A Laird Journal: J Clin Oncol Date: 2015-12-07 Impact factor: 44.544